EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase

Danyun Li, Peiguang Niu, Yanting Zhu, Huajiao Chen, Qiuhua Ding

Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/jcpt/5621631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 05.08.2026. Verfasst von Danyun Li und 4 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Provincial Health Technology Project, Fujian Medical University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic reprogramming contributes to ovarian cancer progression and therapeutic resistance, and glutamine utilization plays a critical role in supporting tumor growth and maintaining redox homeostasis. Cardamonin, a naturally occurring chalcone compound, has demonstrated antitumor activity in several malignancies; however, its effects on glutamine metabolism in ovarian cancer remain unclear.

Methods

Human ovarian cancer SKOV3 and A2780 cells were cultured under glutamine‐sufficient and glutamine‐deprived conditions and treated with cardamonin to evaluate its antiproliferative effects. Cell viability was assessed by CCK‐8 assay. Apoptosis and intracellular reactive oxygen species (ROS) levels were measured by flow cytometry. The expression of glutaminase and mTORC1 pathway‐related proteins was examined by western blotting. In addition, Raptor‐deficient SKOV3 cells were used to further investigate the underlying mechanism.

Results

Cardamonin significantly inhibited ovarian cancer cell proliferation, with more pronounced suppressive effects observed under glutamine‐rich conditions. In addition, cardamonin increased apoptotic cell populations and promoted ROS accumulation in SKOV3 cells. Western blot analysis demonstrated that cardamonin decreased glutaminase expression and reduced phosphorylation of S6K1. Similar suppression of glutaminase expression was observed following rapamycin treatment. Furthermore, Raptor deficiency reduced glutaminase expression and attenuated the inhibitory effects of cardamonin on glutaminase expression and S6K1 phosphorylation.

Conclusions

These findings suggest that cardamonin impairs glutamine‐dependent ovarian cancer cell growth through inhibiting glutaminase expression, which is associated with blockade of the mTORC1 signaling pathway. Collectively, the present study supports glutamine metabolism as a potential therapeutic target of cardamonin in ovarian cancer.

Förderung

  • Fujian Provincial Health Technology Project
  • Fujian Medical University

Zitieren

APA

Li, D., Niu, P., Zhu, Y., Chen, H., & Ding, Q. (2026). Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/5621631

Vancouver

Li D, Niu P, Zhu Y, Chen H, Ding Q. Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/5621631

BibTeX
@article{Li2026,
  author = {Li, Danyun and Niu, Peiguang and Zhu, Yanting and Chen, Huajiao and Ding, Qiuhua},
  title = {Cardamonin Impairs Glutamine‐Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jcpt/5621631}
}
Kostenlos starten →